Quantcast

Latest Low-density lipoprotein Stories

2014-10-23 23:07:59

4 Important Areas To Help Lower Your Cholesterol Naturally. (PRWEB) October 23, 2014 While some cholesterol (the “good” HDLs) is necessary for a body to run properly, too high a level of LDLs (the “bad” ones) can be detrimental to your well-being. These numbers rise when there is an increase of fatty deposits that are built up in the body’s blood vessels, which can constrict the flow of blood. This, in turn, can result in a lack of proper amounts of blood pumping to the heart,...

2014-10-13 12:26:51

LA JOLLA, Calif., Oct. 13, 2014 /PRNewswire-USNewswire/ -- Scientists at The Scripps Research Institute (TSRI) have created a synthetic molecule that mimics "good" cholesterol and have shown it can reduce plaque buildup in the arteries of animal models. The molecule, taken orally, improved cholesterol in just two weeks. This research, published in the October issue of Journal of Lipid Research, points scientists toward a new method for treating atherosclerosis, a condition where...

2014-10-08 12:29:22

WOODBRIDGE, ON, Oct. 8, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that the United Stated Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Pivotal's U.S. Patent Application Serial Number 13/584,403 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids...

2014-10-07 08:28:54

WOODBRIDGE, ON, Oct. 7, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that the United Stated Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Pivotal's U.S. Patent Application Serial Number 13/584,480 titled "STATIN and Omega-3 Fatty Acids for Reduction of...

2014-10-06 16:27:31

INDIANAPOLIS, Oct. 6, 2014 /PRNewswire/ -- PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek® brand and the A1CNow® family of point-of-care diagnostic products, announced today that they have signed a national sales and distribution agreement with Cardinal Health, one of the largest providers of equipment and supplies to the healthcare industry. http://photos.prnewswire.com/prnvar/20141006/150522 "We are excited to add Cardinal to our distribution network," said Robert...

2014-10-03 16:24:21

WOODBRIDGE, ON, Oct. 3, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that on October 1, 2014 it issued 780,722 common shares of the Corporation (the "Common Shares") representing payment of interest for the period of June 5(th), 2014 to September 4(th), 2014 on its outstanding Convertible Notes. Interest on...

2014-10-02 12:32:17

DUBLIN, Oct. 2, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Hypercholesterolemia Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Hypercholesterolemia is defined as a condition characterized by abnormally high levels of total cholesterol and LDL cholesterol in the blood. High cholesterol levels, in turn, can lead to cardiovascular diseases such as atherosclerosis and stroke. The normal physiological range...

2014-10-01 20:24:10

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in...

2014-09-30 23:11:18

GIA announces the release of a comprehensive global report on Cholesterol Testing markets. Global market for Cholesterol Testing is projected to reach 2.9 billion tests by 2020, driven by the surge in health conditions such as diabetes, obesity and hypertension. San Jose, California (PRWEB) September 30, 2014 Follow us on LinkedIn –Cholesterol tests generally measure the level of each type of cholesterol carrier or lipoprotein in the blood. Such tests are essential since the presence of...

2014-09-22 12:31:09

DUBLIN, Sept. 22, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "PCSK9 and Other Novel Hypercholesterolemia Drugs" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously prescribed over the last 25 years. Researchers have concluded that...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin